Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAST 7: RD03/2016 vs Leviosa eye drops after cataract surgery
2026-525594-39-00Phase 3Authorised
- Sponsor
- NTC Pharma
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of NTC014 in cataract (2 arms), sponsored by NTC Pharma. Primary endpoint: Absence of signs of anterior chamber inflammation at Day 8. Planned start Sep 2026; status: authorised.
02
Drugs
NTC014
03
Conditions
cataract
Beyond the preview
Go deeper on 2026-525594-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525594-39-00.